Marianne De Backer - Feb 22, 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Executive Officer, Director
Signature
/s/ Sung Lee, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 22, 2024
Transactions value $
$0
Form type
4
Date filed
2/26/2024, 07:32 PM
Previous filing
Jun 26, 2023
Next filing
Apr 4, 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +175K +30.36% $0.00 751K Feb 22, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +350K $0.00 350K Feb 22, 2024 Common Stock 350K $10.11 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.